SLE Disease Activity Scoring
International guidelines recommend monitoring SLE activity using validated indices such as SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and the Physician Global Assessment (PGA) at each clinical visit. 1
Primary Disease Activity Indices
The most widely validated and recommended tools for scoring SLE disease activity include:
Clinical Activity Indices
- SLEDAI and its modifications (SLEDAI-2K, SELENA-SLEDAI, SLEDAI-2KG) are the most commonly used global activity measures that quantify disease activity across multiple organ systems 1
- BILAG (British Isles Lupus Assessment Group) provides organ-specific activity assessment and better captures changes in individual organ systems, though it is more complex to administer 1
- Physician Global Assessment (PGA) offers a simple 0-10 visual analogue scale assessment that correlates well with other validated measures 1
- SLE-DAS (Systemic Lupus Erythematosus Disease Activity Score) represents a newer comprehensive activity measure 1
Composite Indices for Clinical Trials
- SLE Responder Index (SRI) combines SELENA-SLEDAI, PGA, and BILAG components and has been used extensively in recent clinical trials 1
- BILAG-Based Composite Lupus Assessment (BICLA) provides another validated composite measure 1
Practical Implementation
At Each Clinical Visit
Disease activity must be assessed using a validated index at every patient encounter 1. While these indices were developed primarily for clinical trials, international guidelines emphasize their importance in routine practice despite time constraints 1.
Supporting Laboratory Monitoring
Anti-dsDNA antibodies and complement levels (C3, C4) should be measured at every follow-up visit, even if previously negative or normal 1. These serological markers:
- Support evidence of disease activity or remission 1
- Can predict future flares when elevated 1
- Should be measured using quantitative assays with the same method and laboratory for consistency 1
Additional Monitoring Parameters
Beyond activity scoring, comprehensive assessment requires:
- Annual damage assessment using the SLICC/ACR Damage Index (SDI) to distinguish irreversible organ damage from active disease 1
- Quality of life evaluation at each visit using patient history or a 0-10 VAS scale 1
- Organ-specific assessments for mucocutaneous (using CLASI), renal (proteinuria, creatinine), and neuropsychiatric manifestations 1
Treatment Targets
Therapy should aim for remission (as defined by DORIS criteria) or, if unattainable, lupus low disease activity state (LLDAS) 1. These targets are associated with:
- Reduced damage accrual (OR 0.49-0.75 for remission; OR 0.19-0.88 for LLDAS) 1
- Decreased risk of flares, serious infections, and hospitalizations 1
- Improved long-term outcomes including mortality 1
Defining Treatment Success
- LLDAS: SLEDAI ≤4, PGA ≤1, prednisone ≤7.5 mg/day, well-tolerated immunosuppressants 1
- Complete remission: Absence of clinical activity without glucocorticoids or immunosuppressive drugs (rarely achieved) 1
Common Pitfalls
Time-consuming nature of validated indices often limits their use in routine practice 1. However, failure to use standardized measures leads to:
- Inconsistent disease monitoring across visits
- Inability to objectively track treatment response
- Missed opportunities for early intervention
Do not rely solely on serological markers (anti-dsDNA, complement) without clinical assessment, as serological activity does not always correlate with clinical disease 1. Conversely, normal serology does not exclude active disease requiring treatment adjustment 1.